SCHEMBL24424554

SCHEMBL24424554

CC(C)(C)OC(=O)NC1CCC2(CC1)OCCC2(F)F

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.43
CTSK P43235 2/20 0.40
GAA P10253 2/20 0.39
KDM1A O60341 1/20 0.38
MAOB P27338 1/20 0.38
EPHX1 P07099 1/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
EPHX2 P34913 2/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
CYP2C9 P11712 1/20 0.34
HSD11B1 P28845 1/20 0.34
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
DRD2 P14416 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24424581 0.87 BTK (0.43) BTKCTSKGAAKDM1AMAOB
SCHEMBL28950899 0.82 BTK (0.47) BTKCTSKGAAKDM1AMAOB
SCHEMBL24340475 0.82 BTK (0.47) BTKCTSKGAAKDM1AMAOB
SCHEMBL360739 0.81 BTK (0.50) BTKCTSKGAAKDM1AMAOB
SCHEMBL24424879 0.78 BTK (0.41) BTKCTSKGAAKDM1AMAOB
SCHEMBL509300 0.78 BTK (0.48) BTKCTSKGAAKDM1AMAOB
SCHEMBL12528056 0.78 BTK (0.48) BTKCTSKGAAKDM1AMAOB
SCHEMBL24424041 0.77 BTK (0.40) BTKCTSKGAAKDM1AMAOB
SCHEMBL21774792 0.77 BTK (0.50) BTKCTSKGAAKDM1AMAOB
SCHEMBL21724900 0.77 BTK (0.50) BTKCTSKGAAKDM1AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
EP-4240736-A1 PPAR GAMMA MODULATORS AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2023-09-13 EP disclosed
CN-116635380-A PPARgamma modulators and methods of use 卫材R&D管理有限公司 2023-08-22 CN disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 WO disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD BTK 4512/4885CTSK 2523/4885GAA 2221/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD BTK 3321/4885CTSK 2761/4885GAA 3930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.